Tci Wealth Advisors, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

Tci Wealth Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$16.14 - $24.94 $3,115 - $4,813	193 New	193 $3,000
Q1 2022 Apr 29, 2022	SELL	$41.58 - $80.89 $2,619 - $5,096	-63 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$46.83 - $73.5 $842 - $1,323	18 Added 40.0%	63 $4,000
Q2 2021 Aug 02, 2021	BUY	$37.41 - $62.25 $112 - $186	3 Added 7.14%	45 $2,000
Q1 2021 Apr 29, 2021	BUY	$35.69 - $52.72 $1,498 - $2,214	42 New	42 $2,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.